Local treatment of prosthetic vascular graft infection with multivesicular liposome-encapsulated amikacin

The Journal of Surgical Research
J HuhS E Wilson

Abstract

Contaminated surgical fields limit the use of prosthetic vascular grafts. We studied the efficacy of sustained-release amikacin applied locally to contaminated grafts in the prevention of infectious complications. Thirty-one New Zealand white rabbits underwent placement of a polytetrafluoroethylene (PTFE) interposition graft in a 1-cm segment of the descending aorta. The surgical field was infected with application of 10(5) to 10(8) Staphylococcus aureus organisms suspended in normal saline solution. Nineteen rabbits underwent contaminated aortic graft placement without treatment. Twelve rabbits were treated with local application of 2.5 ml of amikacin encapsulated in lipid particle-based sustained-release dosage form. Rabbits were observed for 2 weeks and then evaluated for the presence of graft infection. Seventy-five percent of the treated rabbits survived without evidence of graft infection or systemic sepsis versus 37% in the untreated group (P < 0.04). Cultures verified the absence of organisms in all surviving rabbits without clinical infection. Sustained-release lipid particle-encapsulated amikacin applied to contaminated PTFE grafts increased survival and decreased postoperative graft infections. Adjunctive use of loca...Continue Reading

References

Dec 1, 1989·The Journal of Surgical Research·J S ShenkM P Bubrick
Jun 1, 1984·American Journal of Surgery·T M BergaminiH C Polk
Mar 9, 1983·Biochimica Et Biophysica Acta·S KimG M Martin
Dec 1, 1994·The Journal of Surgical Research·A L NeyM P Bubrick

❮ Previous
Next ❯

Citations

Feb 22, 2003·Surgical Infections·S E Wilson
Oct 17, 2009·Drug Development and Industrial Pharmacy·Jinna CaoYingjie Deng
Sep 12, 2015·Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia·Takeshiro Fujii, Yoshinori Watanabe
Mar 23, 2007·International Journal of Pharmaceutics·Grazyna GinalskaMonika Osińska
Mar 13, 2003·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·Jürgen PinocyGerhard Ziemer
Jul 19, 2005·International Journal of Pharmaceutics·Haijun ZhongBinghua Yang
Dec 20, 2005·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·A YasimY Ergun
Apr 29, 2011·Current Infectious Disease Reports·Avish Nagpal, Muhammad R Sohail

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.